Cargando…

CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

BACKGROUND: Considering neoadjuvant chemotherapy (NAC) prior to surgery could shrink and reduce the primary tumor and distant micro-metastases to reduce the high relapses rates, NAC has been an accepted therapeutic management for patients with non-small cell lung cancer (NSCLC). CMTM1_v17 is highly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Si, Jiahui, Zhang, Panpan, Tian, Dan, Wang, Xing, Ma, Yuanyuan, Zhang, Jianzhi, Wang, Lu, Yang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273821/ https://www.ncbi.nlm.nih.gov/pubmed/28129775 http://dx.doi.org/10.1186/s12957-016-1094-z

Ejemplares similares

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
por: Guan, Xiudong, et al.
Publicado: (2018)

Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
por: Hong, Yang, et al.
Publicado: (2021)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients
por: Ma, Yuanyuan, et al.
Publicado: (2016)

Effect of visceral pleural invasion on the prognosis of patients with lymph node negative non‐small cell lung cancer
por: Tian, Dan, et al.
Publicado: (2017)

CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer
por: Su, Yu, et al.
Publicado: (2014)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
por: Jia, Daqi, et al.
Publicado: (2023)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer
por: Zhou, Zixuan, et al.
Publicado: (2021)

CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology
por: Knizkova, Daniela, et al.
Publicado: (2022)

Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy
por: Zhang, Panpan, et al.
Publicado: (2016)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders
por: Chen, Shu, et al.
Publicado: (2020)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
por: Li, Jie, et al.
Publicado: (2022)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

Cytoplasmic Kaiso is associated with poor prognosis in non-small cell lung cancer
por: Dai, Shun-Dong, et al.
Publicado: (2009)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling
por: Chen, Zhao-Hui, et al.
Publicado: (2023)

CMTM3 as a Potential New Immune Checkpoint Regulator
por: Shen, Qian, et al.
Publicado: (2022)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis
por: Wang, Zhao, et al.
Publicado: (2019)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
por: Pei, Yulin, et al.
Publicado: (2023)

High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy
por: Yang, Guang, et al.
Publicado: (2015)

Identification of prognostic biomarkers in the CMTM family genes of human ovarian cancer through bioinformatics analysis and experimental verification
por: Zhang, Mengjun, et al.
Publicado: (2022)

Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Zhang, Shidong, et al.
Publicado: (2020)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
por: Jin, Jianjun, et al.
Publicado: (2018)

Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non‐small‐cell lung cancer
por: Ryu, Woo Kyung, et al.
Publicado: (2021)

MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4
por: Zhang, Hongxia, et al.
Publicado: (2015)

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma
por: Zhang, Shusen, et al.
Publicado: (2020)

Overexpression of lncRNA EGFR AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non small cell lung cancer
por: Xu, Yu-Hua, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nnag0cuu7cjq430oqsvjmnhp4u